0001104659-11-032928.txt : 20110602 0001104659-11-032928.hdr.sgml : 20110602 20110602163619 ACCESSION NUMBER: 0001104659-11-032928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20110602 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110602 DATE AS OF CHANGE: 20110602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 11888968 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 8-K 1 a11-13751_18k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): June 2, 2011

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

 

000-30833
(Commission
File Number)

 

04-3110160
(IRS Employer
Identification No.)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 


 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act  (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act  (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 2, 2011, Brian P. Monahan, Chief Financial Officer (“CFO”) of Bruker Corporation (the “Company”), resigned from his position as CFO for personal reasons. Mr. Monahan will remain with the Company and continue to serve as a member of the Company’s senior management team in the role of Vice President of Strategic & Financial Planning.

 

In connection with the resignation of Mr. Monahan from his position as CFO, William J. Knight, age 62, currently Chief Operating Officer, has been appointed interim CFO, effective immediately. Mr. Knight will serve as the Company’s principal financial officer and principal accounting officer while the Company searches for a new CFO to replace Mr. Monahan.  Mr. Monahan will provide support to facilitate a smooth transition of responsibilities.

 

Mr. Knight served as the Company’s CFO from October 2004 until assuming the Chief Operating Officer position in February 2010. Before joining the Company, Mr. Knight served as Chief Financial Officer of Anika Therapeutics, Inc. from 2002 to 2004, as Chief Financial Officer of Zycos, Inc. from 2000 to 2002, and as Chief Financial Officer of NMT Medical, Inc. from 1998 to 2000.  Mr. Knight is a Certified Public Accountant and holds a B.B.A. in Accounting from the University of Wisconsin.

 

Mr. Knight’s current base salary is $362,100. He is eligible to receive an annual performance bonus based on a 2011 bonus target level of $150,000. There were no amendments to Mr. Knight’s salary, bonus eligibility or benefits as a result of his appointment as interim CFO.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)

Exhibits

 

 

 

Number

 

 

 

99.1

Press release dated June 2, 2011.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION

(Registrant)

 

 

Date: June 2, 2011

By:

/s/ William J. Knight

 

 

William J. Knight

 

 

Chief Operating Officer and

Interim Chief Financial Officer

 

3



 

Exhibit Index

 

Exhibit
Number

 

Exhibit Name

 

Location

 

 

 

 

 

99.1

 

Press Release dated June 2, 2011.

 

Furnished herewith*

 


*        Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

4


EX-99.1 2 a11-13751_1ex99d1.htm EX-99.1

Exhibit 99.1

 

Bruker Corporation Announces CFO Transition

 

BILLERICA, Massachusetts, June 2, 2011 (BUSINESS WIRE) - Bruker Corporation (NASDAQ: BRKR) announced today that Brian Monahan has stepped down from his position as Bruker’s Chief Financial Officer (CFO) for personal reasons, in order to spend more time with his young family.

 

William Knight, Bruker’s current Chief Operating Officer and previous CFO, has agreed to serve as Interim CFO, while the Company searches for a new permanent CFO.  Mr. Monahan has accepted the position of Vice President of Strategic & Financial Planning at Bruker, and he intends to work with management to ensure a smooth CFO transition.

 

Frank Laukien, Bruker’s President and Chief Executive Officer, stated: “For the past seven years, Brian has held a number of senior financial and operational positions within Bruker, and his outstanding leadership and integrity have significantly contributed to our commercial and financial success.  I am very pleased that Brian will continue to be part of the Bruker senior management team, and will continue to contribute strongly to our profitable growth strategy.”

 

ABOUT BRUKER CORPORATION

 

For more information about Bruker Corporation, please visit www.bruker.com.

 

FOR FURTHER INFORMATION:

Stacey Desrochers,

 

Director of Investor Relations

 

Tel: +1 (978) 663-3660, ext. 1115

 

Email: stacey.desrochers@bruker.com